Get the Stockscreener App
85.43
1.36%
-1.27
Nuvalent Inc stock is traded at $85.43, with a volume of 101.18K.
It is down -1.36% in the last 24 hours and up +6.74% over the past month.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$86.70
Open:
$86.29
24h Volume:
101.18K
Relative Volume:
0.23
Market Cap:
$6.16B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-24.62
EPS:
-3.47
Net Cash Flow:
$-153.27M
1W Performance:
-0.34%
1M Performance:
+6.74%
6M Performance:
+26.81%
1Y Performance:
+8.56%
1-Day Range:
$84.61
$86.78
1-Week Range:
$83.71
$91.50
52-Week Range:
$61.80
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
85.44 | 6.16B | 0 | -224.29M | -153.27M | -3.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.23 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.00 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.19 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.03 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.79 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Nuvalent (NASDAQ:NUVL) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
The Potential Rise in the Price of Nuvalent Inc (NUVL) following insiders activity - Knox Daily
Nuvalent Inc (NUVL) is looking forward to a strong quarter - SETE News
Top 10 Takeover Targets of 2025 - Genetic Engineering & Biotechnology News
Nuvalent, Inc. (NASDAQ:NUVL) Director Sells $165,580.00 in Stock - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Stock Holdings Raised by SG Americas Securities LLC - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Nuvalent Inc Shares - GuruFocus.com
Nuvalent director Matthew Shair sells shares worth $165,575 - MSN
Nuvalent director Matthew Shair sells shares worth $165,575 By Investing.com - Investing.com Canada
How To Trade (NUVL) - Stock Traders Daily
Bullish Two Hundred Day Moving Average CrossNUVL - Nasdaq
Nuvalent: A First Look (NASDAQ:NUVL) - Seeking Alpha
Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Nuvalent’s (NUVL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Nuvalent stock reiterates buy rating on FDA approval potential - MSN
Nuvalent CEO Porter James Richard sells shares worth $2.05m - MSN
JPMorgan Chase & Co. Has $3.55 Million Stake in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter Sells 27,000 Shares - MarketBeat
Nuvalent CEO Porter James Richard sells shares worth $2.05m By Investing.com - Investing.com Canada
HC Wainwright Reiterates Buy Rating for Nuvalent (NASDAQ:NUVL) - MarketBeat
Nuvalent stock reiterates buy rating on FDA approval potential By Investing.com - Investing.com Canada
Nuvalent's SWOT analysis: biotech stock shows promise amid clinical progress - Investing.com Canada
(NUVL) Trading Report - Stock Traders Daily
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nuvalent Announces Corporate Updates and Anticipated Milestones for 2025 - Defense World
Nuvalent's SWOT analysis: biotech's lung cancer drug stock shows promise amid risks - Investing.com Australia
Nuvalent's SWOT analysis: biotech's lung cancer drug stock shows promise amid risks By Investing.com - Investing.com South Africa
Nuvalent’s (NUVL) Outperform Rating Reaffirmed at Wedbush - Defense World
Nuvalent (NASDAQ:NUVL) Given "Outperform" Rating at Wedbush - MarketBeat
Nuvalent chief legal officer sells shares worth $236,182 By Investing.com - Investing.com Nigeria
Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones - Yahoo Finance
Nuvalent Unveils 'OnTarget 2026' Plan: Accelerates Path to First FDA Approval with Strong Trial Progress - StockTitan
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipate - GuruFocus.com
Nuvalent To Share Updated Data From ARROS-1, ALKOVE-1 Trials In September - RTTNews
Nuvalent: A Logical Acquisition Target (NASDAQ:NUVL) - Seeking Alpha
Nuvalent's chief development officer sells shares worth $320,009 By Investing.com - Investing.com Australia
Nuvalent's chief development officer sells shares worth $320,009 - Investing.com India
Nuvalent chief scientific officer sells shares worth $197,853 - Investing.com India
Nuvalent chief scientific officer sells shares worth $197,853 By Investing.com - Investing.com Canada
Nuvalent CEO James Porter sells shares worth $1.38 million By Investing.com - Investing.com Australia
Nuvalent, Inc. (NASDAQ:NUVL) CFO Sells $319,994.88 in Stock - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells $197,845.44 in Stock - MarketBeat
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvalent Inc Stock (NUVL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shair Matthew | Director |
Jan 27 '25 |
Sale |
82.79 |
2,000 |
165,576 |
218,522 |
| Porter James Richard | President and CEO |
Jan 15 '25 |
Option Exercise |
27.85 |
27,000 |
751,950 |
276,062 |
| Porter James Richard | President and CEO |
Jan 15 '25 |
Sale |
75.99 |
27,000 |
2,051,777 |
249,062 |
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):